Colorectal cancer statistics, 2023
2023/03/01 by Rebecca L. Siegel, Nikita Sandeep Wagle, Andrea Cercek +2 · 50 citations
Medicine · #Colorectal Cancer Screening and Detection #Colorectal Cancer Surgical Treatments #Genetic factors in colorectal cancer
paper · pdf · doi:10.3322/caac.21772
openalex publication_date 2023/03/01 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/31
Abstract
Colorectal cancer (CRC) is the second most common cause of cancer death in the United States. Every 3 years, the American Cancer Society provides an update of CRC statistics based on incidence from population-based cancer registries and mortality from the National Center for Health Statistics. In 2023, approximately 153,020 individuals will be diagnosed with CRC and 52,550 will die from the disease, including 19,550 cases and 3750 deaths in individuals younger than 50 years. The decline in CRC incidence slowed from 3%-4% annually during the 2000s to 1% annually during 2011-2019, driven partly by an increase in individuals younger than 55 years of 1%-2% annually since the mid-1990s. Consequently, the proportion of cases among those younger than 55 years increased from 11% in 1995 to 20% in 2019. Incidence since circa 2010 increased in those younger than 65 years for regional-stage disease by about 2%-3% annually and for distant-stage disease by 0.5%-3% annually, reversing the overall shift to earlier stage diagnosis that occurred during 1995 through 2005. For example, 60% of all new cases were advanced in 2019 versus 52% in the mid-2000s and 57% in 1995, before widespread screening. There is also a shift to left-sided tumors, with the proportion of rectal cancer increasing from 27% in 1995 to 31% in 2019. CRC mortality declined by 2% annually from 2011-2020 overall but increased by 0.5%-3% annually in individuals younger than 50 years and in Native Americans younger than 65 years. In summary, despite continued overall declines, CRC is rapidly shifting to diagnosis at a younger age, at a more advanced stage, and in the left colon/rectum. Progress against CRC could be accelerated by uncovering the etiology of rising incidence in generations born since 1950 and increasing access to high-quality screening and treatment among all populations, especially Native Americans.
Citations
Cited by
- Cancer treatment and survivorship statistics, 2025
- Resveratrol: biology, metabolism, and detrimental role on the tumor microenvironment of colorectal cancer
- ColonAdapter: Geometry Estimation Through Foundation Model Adaptation for Colonoscopy
- Insulin resistance in cancer risk and prognosis
- Automated Delineation of Couinaud Segments at CT for Future Liver Remnant Volumetry
- Genomic Map of Escherichia coli and Single Nucleotide Polymorphism Markers in Colorectal Cancer
- PRKN-mediated the ubiquitination of IQGAP3 regulates cell growth, metastasis and ferroptosis in early-onset colorectal cancer
- Gut decisions based on the liver: A radiomics approach to boost colorectal cancer screening
- “Hurdles race for CAR T‐cell therapy in digestive tract cancer”
- Apoptosis and mitochondrial DNA damaged induced by Zn2 + /Ca2+ dual-ions overload for colorectal cancer improved immunotherapy
- Coding Inequity: Assessing GPT-4’s Potential for Perpetuating Racial and Gender Biases in Healthcare
- Circadian Regulation of Drug Responses: Toward Sex-Specific and Personalized Chronotherapy
- Population-level cancer trends among solid organ transplant recipients in the United States during 1995-2021
- Patient-Derived Tumor Organoids: A Platform for Precision Therapy of Colorectal Cancer
- Anticancer Potential, Phenolic Profile, and Antioxidant Properties of Synsepalum dulcificum (Miracle Berry) in Colorectal Tumor Cell Lines
- Regional patterns of early-onset colorectal cancer from the GEOCODE (Global Early-Onset COlorectal Cancer DatabasE)-European consortium: retrospective cohort study
- Plant-based diet and colorectal cancer: a systematic review and meta-analysis of prospective cohort studies
- Advancements in the use of cancer nanovaccines: Comprehensive insights with focus on lung and colon cancer
- Allura Red AC is a xenobiotic. Is it also a carcinogen?
- Mailed Outreach for Colorectal Cancer Screening in Community Health Centers
- UltraLight Med-Vision Mamba for Classification of Neoplastic Progression in Tubular Adenomas
- Leading Cancer Deaths in People Younger Than 50 Years
- Multiscale Feature Fusion Booster Network for Segmentation of Colorectal Polyp
- An Immune Infiltration-Based Risk Scoring System for Prognostic Stratification in Colorectal Adenocarcinoma
- Microwave dynamic therapy induces ferroptosis in colorectal cancer by targeting PTK2B to regulate STAT3-mediated GPX4 expression
- Deep Learning-based Biological Anatomical Landmark Detection in Colonoscopy Videos
- Molecular Mechanisms of Western Diet-Induced Obesity and Obesity-Related Carcinogenesis-A Narrative Review. [europepmc]
- Role of Epithelial to Mesenchymal Transition in Colorectal Cancer. [europepmc]
- Colorectal Cancer: Disease Process, Current Treatment Options, and Future Perspectives. [europepmc]
- The Importance of Optimal Thermal Ablation Margins in Colorectal Liver Metastases: A Systematic Review and Meta-Analysis of 21 Studies. [europepmc]
- Colorectal Cancer: Current Updates and Future Perspectives. [europepmc]
- Mitochondrial dynamics and colorectal cancer biology: mechanisms and potential targets. [europepmc]
- Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer. [europepmc]
- Niosomes: Composition, Formulation Techniques, and Recent Progress as Delivery Systems in Cancer Therapy. [europepmc]
- Sex differences in colorectal cancer: with a focus on sex hormone-gut microbiome axis. [europepmc]
- The m 6 A modification mediated-lncRNA POU6F2-AS1 reprograms fatty acid metabolism and facilitates the growth of colorectal cancer via upregulation of FASN. [europepmc]
- PI3K/Akt/mTOR Signaling Pathway as a Target for Colorectal Cancer Treatment. [europepmc]
- Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy. [europepmc]
- Colorectal Cancer: Epidemiology, Risk Factors, and Prevention. [europepmc]
- Current advance of nanotechnology in diagnosis and treatment for malignant tumors. [europepmc]
- Targeting circ-0034880-enriched tumor extracellular vesicles to impede SPP1 high CD206 + pro-tumor macrophages mediated pre-metastatic niche formation in colorectal cancer liver metastasis. [europepmc]
- Hematopoietic aging promotes cancer by fueling IL-1⍺-driven emergency myelopoiesis. [europepmc]
- USPSTF Colorectal Cancer Screening Recommendation and Uptake for Individuals Aged 45 to 49 Years. [europepmc]
- Exosomal miR-106a-5p from highly metastatic colorectal cancer cells drives liver metastasis by inducing macrophage M2 polarization in the tumor microenvironment. [europepmc]
- Cancer Prevalence across Vertebrates. [europepmc]
- Digestive cancers: mechanisms, therapeutics and management. [europepmc]
- Cancer statistics, 2025. [europepmc]
- Cancer statistics for African American and Black people, 2025. [europepmc]
- Cancer treatment and survivorship statistics, 2025. [europepmc]
- Clinical Validation of a Circulating Tumor DNA-Based Blood Test to Screen for Colorectal Cancer. [europepmc]
- Early-Onset Gastrointestinal Cancers: A Review. [europepmc]
Related